| Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease |
43 |
| The gut microbiota-derived metabolite trimethylamine N-oxide is elevated in Alzheimer's disease |
36 |
| Advantages and disadvantages of the use of the CSF Amyloid (A) 42/40 ratio in the diagnosis of Alzheimer's Disease |
33 |
| FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac an active immunotherapy against tau protein pathology in Alzheimer's disease |
25 |
| Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE) |
23 |
| Characterization and clinical use of inflammatory cerebrospinal fluid protein markers in Alzheimer's disease |
20 |
| The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias |
20 |
| The rights of precision drug development for Alzheimer's disease |
19 |
| Tau passive immunization blocks seeding and spread of Alzheimer hyperphosphorylated Tau-induced pathology in 3 x Tg-AD mice |
19 |
| Alzheimer's disease phospholipase C-gamma-2 (PLCG2) protective variant is a functional hypermorph |
18 |
| F-18-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes |
17 |
| Altered microRNAs related to synaptic function as potential plasma biomarkers for Alzheimer's disease |
17 |
| Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic |
17 |
| Clinical prevalence of Lewy body dementia |
17 |
| In vivo quantification of neurofibrillary tangles with [F-18]MK-6240 |
17 |
| A single-nuclei RNA sequencing study of Mendelian and sporadic AD in the human brain |
17 |
| Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer's disease |
16 |
| Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer's disease |
16 |
| Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer's disease: a network meta-analysis of 41 randomized controlled trials |
16 |
| Gantenerumab reduces amyloid-beta plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis |
16 |
| Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results |
15 |
| Vulnerability and resilience to Alzheimer's disease: early life conditions modulate neuropathology and determine cognitive reserve |
15 |
| Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease |
15 |
| Effects of spermidine supplementation on cognition and biomarkers in older adults with subjective cognitive decline (SmartAge)study protocol for a randomized controlled trial |
15 |
| Alzheimer's disease master regulators analysis: search for potential molecular targets and drug repositioning candidates |
15 |
| A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation |
14 |
| Alzheimer disease pathology and the cerebrospinal fluid proteome |
14 |
| Systemic and central nervous system metabolic alterations in Alzheimer's disease |
14 |
| Brain volumes and cortical thickness on MRI in the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) |
14 |
| CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia |
13 |
| Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer's disease: randomized, double-blind, placebo-controlled study |
13 |
| Which features of subjective cognitive decline are related to amyloid pathology? Findings from the DELCODE study |
13 |
| Alcohol use and dementia: a systematic scoping review |
13 |
| Amyloid beta-protein oligomers promote the uptake of tau fibril seeds potentiating intracellular tau aggregation |
13 |
| Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer's disease (DELCODE) |
12 |
| White matter microstructure is altered in cognitively normal middle-aged APOE-epsilon 4 |
12 |
| Depression, subjective cognitive decline, and the risk of neurocognitive disorders |
12 |
| Variability in metabolic parameters and risk of dementia: a nationwide population-based study |
12 |
| Spatial patterns of white matter hyperintensities associated with Alzheimer's disease risk factors in a cognitively healthy middle-aged cohort |
12 |
| Brain glucose metabolism in Lewy body dementia: implications for diagnostic criteria |
11 |
| FDG-PET as an independent biomarker for Alzheimer's biological diagnosis: a longitudinal study |
11 |
| Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study |
11 |
| The EMIF-AD PreclinAD study: study design and baseline cohort overview |
11 |
| Consecutive sessions of transcranial direct current stimulation do not remediate visual hallucinations in Lewy body dementia: a randomised controlled trial |
11 |
| Is intracranial volume a suitable proxy for brain reserve? |
11 |
| Prevalence and risk of progression of preclinical Alzheimer's disease stages: a systematic review and meta-analysis |
11 |
| The quest for synergy between physical exercise and cognitive stimulation via exergaming in people with dementia: a randomized controlled trial |
11 |
| Brain and cognitive correlates of subjective cognitive decline-plus features in a population-based cohort |
11 |
| Early brain connectivity alterations and cognitive impairment in a rat model of Alzheimer's disease |
11 |
| Neurofilament light as a blood biomarker for neurodegeneration in Down syndrome |
10 |
